Navigation Links
Study yields clues about the evolution of epilepsy
Date:1/6/2009

Troy, N.Y. Two children have a seizure. One child never has another seizure. Twenty years later, the other child has a series of seizures and is diagnosed with epilepsy. A study being led by researchers at Rensselaer Polytechnic Institute is looking at what could possibly happen in the development of these two children that would lead to such extreme variations in their neurologic health.

The findings reveal that genetic predisposition, coupled with the occurrence of a patient's first seizures, could set the neurologic stage for the later onset of epilepsy. The researchers are now on the hunt to determine what blip in the genetic code could separate a child who will develop epilepsy from a child who will not.

The team's latest research, which is being published in the January edition of Experimental Neurology, is led by Russell Ferland, an assistant professor of biology at Rensselaer within the Center for Biotechnology and Interdisciplinary Studies, and his graduate student Dominick Papandrea, in collaboration with Bruce Herron of the University at Albany and the Wadsworth Center.

To help understand seizure behavior in humans, the researchers first looked to understand the behavior in animal models. In particular, they analyzed specific strains of mice that exhibit striking seizure predispositions, which could offer a glimpse into why epilepsy only develops in certain patients following initial seizures.

One strain is predisposed to have a high resistance to seizures, but that resistance decreases over time as multiple seizures occur. When this strain was examined for seizures after a month, the resistance remained low, indicating a long-lasting change in seizure resistance. Strikingly, the type of seizure was remarkably different after the one-month rest period, Ferland said. Prior to the rest period, the seizures were classic clonic seizures, involving rapid shaking of the limbs. After the rest period, the seizur
'/>"/>

Contact: Gabrielle DeMarco
demarg@rpi.edu
518-276-6542
Rensselaer Polytechnic Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...2 Holly Potter, vice president, Pu...agement for Kaiser Permanente, received the "PR Te...held at the National Press Club. ,, PR News,...nnovators and professionals who day in and day out...ce. The winners of this year,s program set the ben...
(Date:12/2/2009)...., Dec. 2 From more than 1,100 pho...ning, joy and peace, the LIFE Foundation has selec...d using the popular photo-sharing Web site flickr....ontage on the LIFE Foundation,s Web site at www.l...submitted one photo and a caption to Flickr.com du...
(Date:12/2/2009)...c. 2 US Farms, Inc. (Pin..., Nursery and Wellness products, is pleased to ann...ts at the Cook,sware A,faire in Oakland, Calif., a...or additional information, contact US Farms, Inc. ...it http://cookswareafaire.com ,, Victor Brand...
(Date:12/2/2009)...., Dec. 2 Watson Pharmac... the Federal Trade Commission (FTC) has accepted a...g to Watson,s pending acquisition of privately hel... the Hart Scott Rodino waiting period, thereby per... parties have now obtained all regulatory approval...
(Date:12/2/2009)...Red Cross also part of the Hewlett-Packard Company...2 The Hewlett-Packard C...lion this year to help fund American Red Cross dis...com/cgi-bin/prnh/20090108/RedCrossLOGO ) ,, Th...p Philippine communities affected by typhoons in S...
Breaking Medicine News(10 mins):Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 2Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 3Health News:Wonders of Life Photo Contest Winners Announced 2Health News:Wonders of Life Photo Contest Winners Announced 3Health News:US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo 2Health News:Watson Receives FTC Clearance for Arrow Acquisition 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 3
...rs , , President, Campaign for Tobacco-Free Kids ...delivered a tremendous victory for children,s heal...cluding a 61-cent increase in the cigarette tax, t...illions of children both by reducing tobacco use -...
...cuts complications that could cost them a limb , ...ombination of bone cement and antibiotics may help...mpound (open) fractures suffered by U.S. soldiers ...bacter baumannii is common in the Middle East and...
...hursday, February 5th, GlaxoSmithKline plc (NYSE: ...ts for the year ended December 31, 2008. The anno...ock Exchange at approximately 7:00 AM Eastern St...ng for analysts and investors. The meeting is avai...
.../PRNewswire-Asia/ -- Chindex International, Inc.,(...rovider of western healthcare,products and service...ed that,it plans to release fiscal third quarter 2...al results. , To participate in the conference...
...ALO ALTO, Calif., Jan. 29 ,Diagnosoft, Inc., an in...software that assists in diagnosis, staging and th...s announced the closing of $4 million in Series B...f,Diagnosoft(R) HARP(TM), Diagnosoft(R) PLUS, and ...
...andards offer framework for employers , , WASHING...t accreditation body, and the National Business Co...nsive PBM Purchasers Guide for employers and busin...Managing PBM Services is available as a free downl...
Other Medicine News:Health News:U.S. Senate Acts to Protect Kids, Save Lives by Increasing Federal Tobacco Taxes 2Health News:Old Tech Helps Soldiers With New Wound Infection 2Health News:Chindex International, Inc. to Report Fiscal Third Quarter 2009 Financial Results 2Health News:Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO 2Health News:Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO 3Health News:Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO 4Health News:PBM Purchaser Guide from URAC and NBCH Will Help Employers and Business Coalitions Evaluate, Manage Pharmacy Benefit Services 2Health News:PBM Purchaser Guide from URAC and NBCH Will Help Employers and Business Coalitions Evaluate, Manage Pharmacy Benefit Services 3
(Date:12/2/2009)...ecember 2 Cardio Vascula...per of advanced,cardiovascular surgery technology,...tors approved a one-for-three forward stock split,...o Vascular Medical Device shareholders. , ...ated date the stock,split will be payable and the ...
(Date:12/2/2009)...2 Roche (SIX: RO, ROG; O...s Food & Drug Administration (FDA) approved an...acid test, to screen source plasma in pools compri...lled the cobas® TaqScreen MPX Test for use on...tro test for the simultaneous, direct detection of...
(Date:12/2/2009)...., Dec. 2 Novartis announced today...tion on Tasigna® (nilotinib) 200 mg capsules ... the strength of the company,s hematology portfoli...w data, at the 51st American Society of Hematology...e company,s current therapies and investigational ...
Breaking Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25American Medical Informatics Association 28AMIA 29 Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certifi 13045 1American Medical Informatics Association 28AMIA 29 Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certifi 13045 2National Coalition of Mental Health Consumer Survivor Organizations Hires Director of Government Relations 51792 1National Coalition of Mental Health Consumer Survivor Organizations Hires Director of Government Relations 51792 2Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 51788 1Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 51788 2
...ene Activity and Metabolic,Enzymes Show How Cells ...zyme A, a Key Player in the Daily Biochemical Rout...2007 /PRNewswire/ -- Investigators at,St. Jude Chi...the,dynamic genetic and biochemical changes that m...le called Coenzyme A (CoA), a key,player in metabo...
...07 /PRNewswire/ -- DiObex,Inc., a privately- held...ent of therapeutics to treat metabolic diseases, t...902, a novel Cortisol,Synthesis Inhibitor. , In a ...bo-controlled trial, patients with type 2 diabetes..., pharmacokinetics and,activity of three dose leve...
Other Medicine Technology:Study Shows Metabolic Strategy of Stressed Cell 2Study Shows Metabolic Strategy of Stressed Cell 3Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 2Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 3
Woodson Elevator
Henner Elevator
Tenzel Double-Ended Periosteal Elevator
DesMarres Lid Retractor
Medicine Products: